+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID06875609

Study of Blood Test Monitoring in Patients With Cutaneous Squamous Cell Carcinoma Undergoing Surgery or Immunotherapy

Led by Massachusetts Eye and Ear Infirmary · Updated on 2026-03-30

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether a blood test that detects circulating tumor DNA ctDNA can help monitor residual disease after surgery and response to immunotherapy in patients with cutaneous squamous cell carcinoma CSCC. This study aims to understand if ctDNA levels can provide real-time insights into tumor recurrence and treatment effectiveness. The ctDNA test is not yet FDA-approved for this use and is being studied as a potential future tool. The study includes patients with CSCC who undergo surgery, neoadjuvant immunotherapy, or definitive immunotherapy as part of their standard care. Participants will have blood and tissue samples collected to analyze changes in ctDNA over time. There are three groups patients treated with surgery, patients receiving neoadjuvant immunotherapy before surgery, and patients receiving definitive immunotherapy without surgery. Participants will be followed for 2 years, with blood samples collected during regular treatment visits or via mobile phlebotomy. Researchers will assess outcomes such as 2-year recurrence-free survival and treatment response based on ctDNA levels. The study involves monitoring ctDNA to evaluate its potential as a biomarker for detecting cancer progression or recurrence while participants receive usual care and treatment.

CONDITIONS

Brief Title

ctDNA in Cutaneous Squamous Cell Carcinoma

Research Team

M

Michael Cheung, MSc, CCRP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here